These medications are one tool, says Kumar
Zepbound is FDA-approved for chronic weight management and may offer enhanced results for patients struggling with obesity or weight-related health concerns
While these drugs can be life-changing, they also come with significant costs for the employers who choose to cover them
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity
23 The FDA recommends that patients remain on each dose of certain GLP-1 RA therapies, namely semaglutide, dulaglutide, and tirzepatide, for at least 4 weeks before dose increases